QN 023a
Alternative Names: QN-023aLatest Information Update: 30 Dec 2022
At a glance
- Originator Qihan Biotech
- Developer Institute of Hematology & Blood Diseases Hospital; Qihan Biotech
- Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Acute myeloid leukaemia
Most Recent Events
- 15 Dec 2022 Zhejiang University in collaboration with Hangzhou Qihan Biotech initiates a phase I trial in Acute myeloid lekukemia (Second-line therapy or greater) in China (Parenteral) (NCT05665075)
- 21 Oct 2022 Phase-I clinical trials in Acute myeloid leukaemia (In adults, In the elderly, Refractory metastatic disease) in China (Parenteral) (NCT05601466)